Based on these findings, we suggest that TLR7 could serve as a novel therapeutic target for the prevention and treatment of NAFLD through improved immune responses, and that TLR7 may be involved in the “two-hit” hypothesis. The gene discussed is TLR7; the disease is metabolic dysfunction-associated steatotic liver disease.